Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins

Clinical Pharmacology and Therapeutics

Volumn 80, Issue 5, 2006, Pages 477-485

  Oswald, Stefan ^a   Giessmann, Thomas ^a   Luetjohann, Dieter ^a   Wegner, Danilo ^a   Rosskopf, Dieter ^a   Weitschies, Werner ^a   Siegmund, Werner ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CAMPESTEROL; CHOLESTEROL; EZETIMIBE; GLUCURONIDE; GLYCOPROTEIN P; LATHOSTEROL; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 2; PHYTOSTEROL; RIFAMPICIN; SITOSTEROL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG FECES LEVEL; DRUG URINE LEVEL; FECES; FEMALE; GAS CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INTESTINE; KIDNEY CLEARANCE; LIPID BLOOD LEVEL; LIQUID CHROMATOGRAPHY; LIVER; MALE; MASS SPECTROMETRY; MONOTHERAPY; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SYSTEMIC CIRCULATION; URINARY EXCRETION;

ADMINISTRATION, ORAL; ADULT; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL; CHROMATOGRAPHY, GAS; CHROMATOGRAPHY, LIQUID; CROSS-OVER STUDIES; ENZYME INHIBITORS; FECES; FEMALE; GENOTYPE; GLUCURONIDES; HUMANS; INTESTINAL ABSORPTION; INTESTINES; MALE; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEINS; PHYTOSTEROLS; RIFAMPIN; SITOSTEROLS; TIME FACTORS;

EID: 33751103450     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2006.07.006     Document Type: Article

References (51)

1. Kunta J.R., and Sinko P.J. Intestinal drug transporters: in vivo function and clinical importance. Curr Drug Metab 5 (2004) 109-124
2. Altmann S.W., Davis Jr. H.R., Zhu L.J., Yao X., Hoos L.M., Tetzloff G., et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 303 (2004) 1201-1204
3. Hui D.Y., and Howles P.N. Molecular mechanisms of cholesterol absorption and transport in the intestine. Semin Cell Dev Biol 16 (2005) 183-192
4. Davies J.P., Scott C., Oishi K., Liapis A., and Ioannou Y.A. Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. J Biol Chem 280 (2005) 12710-12720
5. Yu L.Q., Bharadwaj S., Brown J.M., Ma Y.Y., Du W., Davis M.A., et al. Cholesterol-regulated translocation of NPC1L1 to the cell surface facilitates free cholesterol uptake. J Biol Chem 281 (2006) 6616-6624
6. Patrick J.E., Kosoglou T., Stauber K.L., Alton K.B., Maxwell S.E., Zhu Y., et al. Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metab Dispos 30 (2002) 430-437
7. Ghosal A., Hapangama N., Yuan Y., Achanfuo-Yeboah J., Iannucci R., Chowdhury S., et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia). Drug Metab Dispos 32 (2004) 314-320
8. Tukey R.H., and Strassburg C.P. Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract. Mol Pharmacol 59 (2001) 405-414
9. van Heek M., Farley C., Compton D.S., Hoos L., Alton K.B., Sybertz E.J., et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol 129 (2000) 1748-1754
10. Bergman A.J., Burke J., Larson P., Johnson-Levonas A.O., Reyderman L., Statkevich P., et al. Interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patients. J Clin Pharmacol 46 (2006) 328-336
11. Kosoglou T., Statkevich P., Fruchart J.C., Pember L.J., Reyderman L., Cutler D.L., et al. Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe. Curr Med Res Opin 20 (2004) 1197-1207
12. Reyderman L., Kosoglou T., Statkevich P., Pember L., Boutros T., and Maxwell S.E. Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil. Int J Clin Pharmacol Ther 42 (2004) 512-518
13. Oswald S., Haenisch S., Fricke C., Sudhop T., Remmler C., Giessmann T., et al. Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clin Pharmacol Ther 79 (2006) 206-217
14. Ezzet F., Krishna G., Wexler D.B., Statkevich P., Kosoglou T., and Batra V.K. A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe. Clin Ther 23 (2001) 871-885
15. Schiller C., Frohlich C.P., Giessmann T., Siegmund W., Monnikes H., Hosten N., et al. Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment Pharmacol Ther 22 (2005) 971-979
16. Chandra P., and Brouwer K.L. The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharm Res 21 (2004) 719-735
17. Hagenbuch B., and Meier P.J. The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta 1609 (2003) 1-18
18. Tirona R.G., Leake B.F., Wolkoff A.W., and Kim R.B. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 304 (2003) 223-228
19. Vavricka S.R., Van Montfoort J., Ha H.R., Meier P.J., and Fattinger K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 36 (2002) 164-172
20. Fardel O., Lecureur V., Loyer P., and Guillouzo A. Rifampicin enhances anti-cancer drug accumulation and activity in multidrug-resistant cells. Biochem Pharmacol 49 (1995) 1255-1260
21. Zong J., and Pollack G.M. Modulation of P-glycoprotein transport activity in the mouse blood-brain barrier by rifampin. J Pharmacol Exp Ther 306 (2003) 556-562
22. Furusawa S., Nakano S., Wu J., Sasaki K., Takayanagi M., and Takayanagi Y. Potentiation of pirarubicin activity in multidrug resistant cells by rifampicin. Biol Pharm Bull 20 (1997) 1303-1306
23. Cui Y., Konig J., and Keppler D. Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. Mol Pharmacol 60 (2001) 934-943
24. Lau Y.Y., Okochi H., Huang Y., and Benet L.Z. Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems. J Pharmacol Exp Ther 316 (2006) 762-771
25. Spears K.J., Ross J., Stenhouse A., Ward C.J., Goh L.B., Wolf C.R., et al. Directional trans-epithelial transport of organic anions in porcine LLC-PK1 cells that co-express human OATP1B1 (OATP-C) and MRP2. Biochem Pharmacol 69 (2005) 415-423
26. Oswald S., Scheuch E., Cascorbi I., and Siegmund W. A LC-MS/MS method to quantify the novel cholesterol lowering drug ezetimibe in human serum, urine and feces in healthy subjects genotyped for SLCO1B1. J Chromatogr B Analyt Technol Biomed Life Sci 830 (2006) 143-150
27. Sudhop T., Lutjohann D., Kodal A., Igel M., Tribble D.L., Shah S., et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 106 (2002) 1943-1948
28. Niemi M., Schaeffeler E., Lang T., Fromm M.F., Neuvonen M., Kyrklund C., et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14 (2004) 429-440
29. Miettinen T.A., Tilvis R.S., and Kesaniemi Y.A. Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am J Epidemiol 131 (1990) 20-31
30. Reihner E., Rudling M., Stahlberg D., Berglund L., Ewerth S., Bjorkhem I., et al. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N Engl J Med 323 (1990) 224-228
31. Nebert D.W., and Russell D.W. Clinical importance of the cytochromes P450. Lancet 360 (2002) 1155-1162
32. Kajosaari L.I., Laitila J., Neuvonen P.J., and Backman J.T. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic Clin Pharmacol Toxicol 97 (2005) 249-256
33. Mariappan T.T., and Singh S. Evidence of efflux-mediated and saturable absorption of rifampicin in rat intestine using the ligated loop and everted gut sac techniques. Mol Pharm 1 (2004) 363-367
34. Fromm M.F., Kauffmann H.M., Fritz P., Burk O., Kroemer H.K., Warzok R.W., et al. The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol 157 (2000) 1575-1580
35. Geick A., Eichelbaum M., and Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 276 (2001) 14581-14587
36. Kast H.R., Goodwin B., Tarr P.T., Jones S.A., Anisfeld A.M., Stoltz C.M., et al. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 277 (2002) 2908-2915
37. Ehrhardt M., Lindenmaier H., Burhenne J., Haefeli W.E., and Weiss J. Influence of lipid lowering fibrates on P-glycoprotein activity in vitro. Biochem Pharmacol 67 (2004) 285-292
38. Seral C., Carryn S., Tulkens P.M., and Van Bambeke F. Influence of P-glycoprotein and MRP efflux pump inhibitors on the intracellular activity of azithromycin and ciprofloxacin in macrophages infected by Listeria monocytogenes or Staphylococcus aureus. J Antimicrob Chemother 51 (2003) 1167-1173
39. Shono Y., Nishihara H., Matsuda Y., Furukawa S., Okada N., Fujita T., et al. Modulation of intestinal P-glycoprotein function by cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes. J Pharm Sci 93 (2004) 877-885
40. Yamazaki M., Li B., Louie S.W., Pudvah N.T., Stocco R., Wong W., et al. Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport. Xenobiotica 35 (2005) 737-753
41. Bohme M., Jedlitschky G., Leier I., Buchler M., and Keppler D. ATP-dependent export pumps and their inhibition by cyclosporins. Adv Enzyme Regul 34 (1994) 371-380
42. Koshman S.L., Lalonde L.D., Burton I., Tymchak W.J., and Pearson G.J. Supratherapeutic response to ezetimibe administered with cyclosporine. Ann Pharmacother 39 (2005) 1561-1565
43. Payen L., Courtois A., Campion J.P., Guillouzo A., and Fardel O. Characterization and inhibition by a wide range of xenobiotics of organic anion excretion by primary human hepatocytes. Biochem Pharmacol 60 (2000) 1967-1975
44. Tamai I., and Safa A.R. Competitive interaction of cyclosporins with the Vinca alkaloid-binding site of P-glycoprotein in multidrug-resistant cells. J Biol Chem 265 (1990) 16509-16513
45. Shitara Y., Itoh T., Sato H., Li A.P., and Sugiyama Y. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 304 (2003) 610-616
46. Shitara Y., Hirano M., Sato H., and Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 311 (2004) 228-236
47. Chung J.Y., Cho J.Y., Yu K.S., Kim J.R., Oh D.S., Jung H.R., et al. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 78 (2005) 342-350
48. Hirano M., Maeda K., Shitara Y., and Sugiyama Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 311 (2004) 139-146
49. Kosoglou T., Statkevich P., Johnson-Levonas A.O., Paolini J.F., Bergman A.J., and Alton K.B. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 44 (2005) 467-494
50. Nakai D., Nakagomi R., Furuta Y., Tokui T., Abe T., Ikeda T., et al. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J Pharmacol Exp Ther 297 (2001) 861-867
51. Simonson S.G., Raza A., Martin P.D., Mitchell P.D., Jarcho J.A., Brown C.D., et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 76 (2004) 167-177